Resumen de SEOM clinical guideline of diagnosis and management of low-grade glioma (2017)

Juan Manuel Sepúlveda Sánchez, José Muñoz Langa, Miguel Ángel Arráez Sánchez, José Fuster Salvá, A. Hernández Laín, Gaspar Reynés Muntaner, V. Rodríguez González, E. Vicente Rubio, M. Vidal Denis, O. Gallego Rubio

• Diffuse infiltrating low-grade gliomas include oligodendrogliomas and astrocytomas, and account for about 5% of all primary brain tumors. Treatment strategies for these low-grade gliomas in adults have recently changed. The 2016 World Health Organization (WHO) classification has updated the definition of these tumors to include their molecular characterization, including the presence of isocitrate dehydrogenase (IDH) mutation and 1p/19p codeletion. In this new classification, the histologic subtype of grade II-mixed oligoastrocytoma has also been eliminated. The precise optimal management of patients with low-grade glioma after resection remains to be determined. The risk–benefit ratio of adjuvant treatment must be weighed for each individual.